Loading market dashboard
Oxford Biomedica plc
OXB.LHealthcareLSEGB
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
OXB to demonstrate how its global, multi-vector CDMO platform is positioned to capture growth in the cell and gene therapy marketEvent to highlight OXB's proven track record, leading technical capabilities, expanded international manufacturing network, deep regulatory expertise and strong client partnershipsSets out a vision for long-term growth, with an ambition to achieve revenues of c.
Oxford Biomedica plc (LON: OXB - Get Free Report) shares passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of GBX 663.18 and traded as low as GBX 559. Oxford Biomedica shares last traded at GBX 571.98, with a volume of 162,434 shares traded. Analyst Ratings Changes
New expedited service line designed for biotechs with timeline constraints, launched in response to client demandCan accelerate timeline to GMP manufacturing by up to nine months, driven by key innovations and efficiencies across upstream and downstream processes Oxford, UK - 13 April 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces the launch of its new fast-track development and manufacturing offering, providing an expedited route to GMP manufacture for clients utilising lentiviral (LV) and adeno-associated viral (AAV) vectors.
Oxford Biomedica plc (LON: OXB - Get Free Report)'s share price crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of GBX 663.38 and traded as low as GBX 544. Oxford Biomedica shares last traded at GBX 560, with a volume of 11,794,788 shares changing hands. Wall
Oxford Biomedica (LON: OXB) outlined a year of revenue growth, a return to operating EBITDA profitability, and continued expansion of its global viral vector CDMO network during its preliminary full-year 2025 results call. Management emphasized that 2025 reflected "sustained commercial momentum and disciplined execution," supported by rising demand across vector types and more client programs advancing
Oxford, UK - 27 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised with the 'Most Innovative CDMO (Cell and Gene Therapy)' award at the CDMO Leadership Awards in New York City.
A year of strategic execution, strong revenue growth and positive Operating EBITDA Strong 2025 financial performance; revenues at upper end of guidance, with full year Operating EBITDA profitability achieved: Revenue growth of 33% to £170. 9 million (CC) (FY 2024: £128. 8 million) Operating EBITDA profit of £8. 1 million (CC) (FY2024: £(15. 3) million), driven by revenue growth and increasing focus on operating costs, and including one-off gain from the acquisition of the Durham, North Carolina (NC) facility.
Shares of Oxford Biomedica plc (LON: OXB - Get Free Report) crossed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of GBX 663.97 and traded as low as GBX 630. Oxford Biomedica shares last traded at GBX 648, with a volume of 353,135 shares. Analysts Set New
